Highest-materiality recent filing
Protagenic Therapeutics terminates CFO Alexander Arrow, effective April 30, 2026
CFO Alexander Arrow notified on March 31, 2026 that employment will be terminated.
William (Bill) Nichols, Jr., age 51, appointed President effective Feb 3, 2026.
Protagenic Therapeutics unwinds Phytanix Bio acquisition, pays $310k, settles litigation
Settlement and Unwind Agreement executed Feb 17, 2026; SEA dated May 15, 2025 terminated.
Protagenic Therapeutics receives Nasdaq delisting notice; trading to move to OTC Jan 5, 2026
Nasdaq determined to delist PTIX and PTIXW due to failure to meet minimum stockholders' equity (Rule 5550(b)(1)) and timely filing (Rule 5250(c)(1)).
Protagenic Therapeutics receives Nasdaq delisting notice for equity and filing non-compliance
Stockholders' equity fell below $2.5M minimum per Listing Rule 5550(b)(1) as of June 30, 2025.
Director Jennifer Chao resigns from Protagenic Therapeutics Board
Jennifer Chao resigned from the Board of Directors on November 3, 2025, effective immediately.
Protagenic Therapeutics files suit to rescind Phytanix Bio acquisition or seek damages
Filed Verified Complaint in Delaware Chancery Court on October 28, 2025.
Protagenic Therapeutics updates auditor consent for Phytanix acquisition; no material news
Company files Exhibit 23.1 with consent of GreenGrowth CPAs Inc.
Protagenic restructures after Phytanix acquisition; CEO/COO out, targets $8M savings
Acquired Phytanix Bio on May 15, 2025 via share exchange; gained five preclinical candidates (PHYX-001 to -005).
Protagenic: Nasdaq non-compliance for late 10-Q; auditor changed; PT00114 Phase I dosing complete
Dismissed MaloneBailey as auditor, engaged Green Growth CPAs as new independent auditor effective August 7, 2025.
Protagenic Therapeutics restructures, cuts ~$8M annual costs; CEO and COO terminated
Board approved restructuring to virtual model, focusing on PT00114 Phase 2 trial expected to complete in 9–12 months.
Protagenic Therapeutics granted Japan patent for modified stilbenoid epilepsy drug candidates
Japanese Patent Office granted Patent JP 7714571B on July 18, 2025, covering modified stilbenoid compounds.
Protagenic Therapeutics appoints Timothy R. Wright as Class II director
Timothy R. Wright appointed to board effective July 18, 2025 as Class II director, term expires at 2026 annual meeting.
Board authorized distribution of one Right per common share held as of July 7, 2025 record date.
Protagenic Therapeutics receives $3.1M from warrant exchanges and exercises
Warrant exchanges and exercises over the last four trading days generated $3.1M in cash.
Protagenic Therapeutics exchanges 459,420 warrants for 367,544 shares at 0.8 ratio
Warrant Exchange Agreement with unaffiliated holder to cancel 459,420 warrants for 367,544 common shares.
Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors
Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025
Protagenic Therapeutics effects 1-for-14 reverse stock split to meet Nasdaq bid price rule
Reverse stock split at 1-for-14 ratio effective 12:01 a.m. ET on May 5, 2025.
Protagenic Therapeutics approves 1-for-14 reverse stock split effective May 5, 2025
Reverse stock split at 1-for-14 ratio, effective 12:01 a.m. ET on May 5, 2025.
Protagenic shareholders approve reverse stock split at ratio 1:10 to 1:20
Special Meeting held April 18, 2025; 4,049,963 shares present out of 7,241,443 entitled.
Protagenic Therapeutics shareholders approve all five proposals at 2024 annual meeting
Elected Garo H. Armen and Brian J. Corvese as Class III directors with ~1.87M and ~1.85M for votes.
Protagenic Therapeutics reprices outstanding stock options to $0.2655 per share
Stockholders approved repricing of options under 2006 and 2016 Equity Incentive Plans.
Protagenic receives Nasdaq delisting notice for failing to regain $1 bid price compliance
Nasdaq notified on Jan 22, 2025 that company failed to regain compliance with minimum bid price Rule 5550(a)(2).
Protagenic Therapeutics gets Nasdaq notice for missing annual meeting; sets Feb 21, 2025 meeting
Received Nasdaq notice on Jan 15, 2025 for failing to hold annual meeting within 12 months of FY 2023 end (Listing Rule 5620(a)).
Protagenic Therapeutics enters ATM sales agreement for up to $1.2M with B. Riley Securities
Amendment No. 1 to At Market Issuance Sales Agreement with B. Riley Securities, dated Jan 9, 2025.
Protagenic Therapeutics appeals Nasdaq delisting; hearing set for Jan 30, 2025
Nasdaq determined non-compliance with $2.5M stockholders' equity requirement (Rule 5550(b)(1)).
Protagenic Therapeutics receives Nasdaq delisting notice; stock suspension set for Nov 29
Failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement by Nov 18, 2024, after extension.
Protagenic Therapeutics closes $1.275M private placement of common stock and warrants
Closed private placement on Nov 4, 2024; sold 1,948,295 shares of common stock.
Protagenic Therapeutics raises $1.275M in private placement of common stock and warrants
Issued 1,948,295 shares (or pre-funded warrants) at $0.64 per share ($0.89 for insiders).
Protagenic Therapeutics updates PT00114 milestones: Phase I multi-dose Q4 2024, Phase IIa Q3 2025
Multiple dose portion of Phase I study for PT00114 expected to commence Q4 2024.
Nasdaq notified PTIX on July 24, 2024 of non-compliance with minimum $1.00 bid price for 30 consecutive business days.
Protagenic Therapeutics receives Nasdaq deficiency notice for failing minimum equity requirement
Company's stockholders' equity fell below Nasdaq's $2.5M minimum as of March 31, 2024.
Phase 1 single dose trial completed with 30 subjects across five cohorts up to 1,000 micrograms; no clinically-relevant adverse events.
Protagenic Therapeutics resolves Nasdaq delisting notice, regains compliance with bid price rule
Regained compliance with Nasdaq Listing Rule 5550(a)(2) on March 19, 2024.
Protagenic Therapeutics reports 2023 annual meeting voting results; two Class II directors elected
Robert B. Stein, MD, PhD elected with 974,293 votes for, 56,765 withheld; Jennifer Buell, PhD elected with 963,089 for, 67,969 withheld.
Protagenic Therapeutics receives Nasdaq minimum bid price deficiency notice
Nasdaq notified PTIX on Nov 21, 2023 that common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
Reverse split effective 5:01 p.m. ET March 22, 2023; split-adjusted trading Nasdaq opens March 23, 2023.
Shareholders approve reverse split; company updates PT00114 trial timeline
Stockholders approved a reverse stock split of 1:2 to 1:4, with board discretion on exact ratio.
Protagenic receives CMC questions from European regulator; expects Q4 2022 trial start
Received CMC (Chemistry, Manufacturing and Controls) questions from a European regulatory authority on August 30, 2022.
Company completing requirements to answer regulatory questions and begin US re-submission process.
Protagenic Therapeutics resolves Nasdaq audit committee compliance issue, appoints Joshua Silverman
Nasdaq notified the Company of audit committee composition non-compliance from April 27 to September 30, 2021.
Protagenic Therapeutics stockholders approve classified board structure; directors re-elected
At Sep 29 annual meeting, all six director nominees elected with votes ranging from 8.37M to 8.88M for each.
Protagenic Therapeutics delays PT00114 trial start to Jan 2022; Q2 net loss $2.6M
FDA required ready-to-inject vials; IND re-filing moved to Q4 2021, Phase I/IIa start to Jan 2022.
Protagenic Therapeutics delays PT00114 clinical trial start to Q4 2021 after FDA request
FDA requested ready-to-inject clinical vials instead of local formulation; company refiling IND.
Protagenic Therapeutics enters ATM equity offering agreement for up to $10M
Entered into ATM Sales Agreement with B. Riley Securities and EF Hutton to sell up to $10M of common stock.
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
Colin Stott as Chief Operating Officer and as a director of the Company
Colin Stott as Chief Operating Officer and as a director of the Company
Jennifer Chao as a director of the Company
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
promoted Andrew Slee from his prior role of Chief Operating Officer to the Company’s Chief Development Officer, effective immediately upon the Closing on May 15, 2025
Max materiality 0.90 · Median 0.60 · Most common event other_material